期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 80, 期 4, 页码 853-867出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2018.05.1260
关键词
booster therapy; ciclopirox; clinical cure; complete cure; efinaconazole; fluconazole; fungal nail infection; itraconazole; lasers; mycologic cure; onychomycosis; photodynamic therapy; plasma therapy; pulse dosing; tavaborole; terbinafine; treatment
类别
Onychomycosis is a fungal nail infection caused by dermatophytes, nondermatophytes, and yeast, and is the most common nail disorder seen in clinical practice. It is an important problem because it may cause local pain, paresthesias, difficulties performing activities of daily living, and impair social interactions. The epidemiology, risk factors, and clinical presentation and diagnosis of onychomycosis were discussed in the first article in this continuing medical education series. In this article, we review the prognosis and response to onychomycosis treatment, medications for onychomycosis that have been approved by the US Food and Drug Administration, and off-label therapies and devices. Methods to prevent onychomycosis recurrences and emerging therapies are also described.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据